rs115071742 - MIR548H4 - STMN4

Magnitude 4.5 · 1 study on file

Reported associations

• Association between metformin medication, genetic variation and prostate cancer risk. - Prostate cancer and prostatic diseases (2021) · Lee MJ, Jayalath VH, Xu W, Lu L, Freedland SJ, Fleshner NE, Kulkarni GS, Finelli A, van der Kwast TH, Hamilton RJ · PubMed 32424261

  The relationship between metformin use and prostate cancer risk remains controversial. Genetic variation in metformin metabolism pathways appears to modify metformin glycemic control and the protective association with some cancers. However, no studies to date have examined this pharmacogenetic interaction and prostate cancer chemoprevention. Clinical data and germline DNA were collected from our prostate biopsy database between 1996 and 2014. In addition to a genome-wide association study (GWAS), 27 single nucleotide polymorphisms (SNPs) implicated in metformin metabolism were included on a custom SNP array. Associations between metformin use and risk of high-grade (Grade Group ≥ 2) and overall prostate cancer were explored using a case-control design. Interaction between the candid

Auto-generated from study metadata. AI-synthesised commentary is added when this entry is regenerated through content-service's LLM mode.